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Introduction
Non-albicans Candida (NAC) yeast-like fungi play 
a more active role in fungal infections. Candida glabrata, 
one of the most important yeast-like fungi of this group, 
is the second most common cause of candidiasis.
Distribution of C. glabrata varies depending on 
the geographical area. Relatively high incidence of 
C. glabrata was observed in the northern part of Europe 
and in the USA in contrary to southern countries of 
Europe and Latin America where C. parapsilosis infec-
tions are more often found.
The global prevalence of C. albicans is decreasing, 
in contrary to C. glabrata and C. krusei, which remain 
stable. The incidence of C. parapsilosis and C. tropicalis 
is increasing. It was also demonstrated that C. glabrata 
is more often isolated from elderly patients (Falagas 
et al. 2010; Alexander et al. 2013; Guinea 2014).
The reason for the change in the profile of Candida 
infection remains unknown, however, an increase in 
NAC infections, especially C. glabrata, seems to be 
attributable to unreasonable antifungal prevention 
(Basetti et al. 2009; Gołaś et al. 2014). C. glabrata candi-
demias are on the increase (Quindós 2014). In ten years 
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A b s t r a c t
The data on susceptibility to antifungals of new species within Candida glabrata complex are limited. Our study was to enrich a global 
knowledge of yeast epidemiology and drug resistance. The study was focused on the identification of species within clinical isolates of the 
C. glabrata complex and on the determination of their resistance to antifungals. Four hundred forty-five clinical C. glabrata sensu lato strains 
were isolated from different clinical samples at routine mycological exams at the Infant Jesus Teaching Hospital in Warsaw. The identifica-
tion of the most of tested isolates to species complex level was performed using the ID 32 C system. The identification of C. nivariensis 
and C. bracarensis species within the C. glabrata complex was performed by DNA sequencing. The MICs of amphotericin B, fluconazole, 
itraconazole, posaconazole, voriconazole, caspofungin, anidulafungin, and micafungin were determined by E-test. Twenty-four isolates 
did not have an ITS-1 region, characteristic of C. glabrata sensu stricto and their D1/D2 regions of the 26S rRNA were 99% homologous 
to C. nivariensis 26S rRNA. No strains of C. bracarensis were recovered. C. nivariensis strains were very susceptible to amphotericin B, 
anidulafungin, micafungin, and caspofungin. Ninety-two percent of C. nivariensis were resistant to itraconazole. The halves of the strains 
was resistant to posaconazole. Eighty-three percent of C. nivariensis were susceptible to voriconazole. None of the tested strains were sus-
ceptible to fluconazole. In the present study, none of the C. nivariensis strains were simultaneously resistant to azoles and echinocandins. 
C. nivariensis should be recognized as an emerging pathogen, resistant to azoles.
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(since 1989) C. glabrata candidemias have increased 
from the fourth to the second most common cause of 
ICU infections (Lockhart et al. 2012).
Nowadays, the C. glabrata species complex has been 
identified including three closely related new species: 
C. glabrata sensu stricto, C. nivariensis, and C. bracarensis 
(Alcoba-Flórez et al. 2005; Miranda-Zapico et al. 2011).
C. nivariensis and C. bracarensis represented less 
than 5% within the C. glabrata complex (Bishop et al. 
2008; Lockhart et al. 2009; Sharma et al. 2013). C. niva­
riensis was more frequently isolated than C. bracarensis. 
These species could become the new sources of oppor-
tunistic infections. However, the mycological routine 
diagnostics cannot differentiate between C. glabrata 
sensu stricto, C. bracarensis, and C. nivariensis. It can 
only classify these species as a part of the C. glabrata 
species complex. A complete species differentiation 
within the complex may be achieved with molecular 
biology techniques, which can identify closely related 
yeast-like fungi (Angoulvant et al. 2016). In order to 
assess the clinical impact of the new species within the 
C. glabrata species complex, it is important to determine 
their virulence factors. Virulence factors enable yeast-
like fungi to begin and carry out the subsequent stages of 
an infection. Amongst the most important pathogenic-
ity determinants of C. glabrata sensu lato is their ability 
to adhere to abiotic and biotic surfaces, to form biofilm 
on both surfaces, and to secrete phospho- and lipases, 
hemolysins, and other cytotoxic enzymes. (Tamura et al. 
2007; Silva et al. 2012; Rodrugues et al. 2014).
Little is known about the drug resistance of the 
C. glabrata species complex. Some studies suggest 
that the new species within the complex may be more 
resistant to antifungals than C. glabrata sensu stricto 
(Tamura et al. 2007; Silva et al. 2012; Li et al. 2014, 
Rodrugues et al. 2014; Angoulvant et al. 2016). C. niva­ 
riensis and C. bracarensis, two new species recently 
discovered, exhibit many traits common to C. glabrata 
sensu stricto, but are isolated less frequently. Despite 
being detected more commonly, these two species are 
still unknown and require further investigation.
This study was to identify the clinical species within 




Four hundred forty-five clinical C. glabrata sensu 
lato strains were isolated from different clinical samples 
(urine – 154, tracheal aspirate – 63, throat swab – 44, 
sputum – 34, feces – 32, peritoneal fluid – 27, skin ulcer 
– 26, vagina – 18, post-surgical wound drainage – 12, 
bile – 11, blood – 7, bronchoalveolar lavage – 7, other 
– 10) at routine mycological exams at the Infant Jesus 
Teaching Hospital in Warsaw in the years from 2014 to 
2016. All samples were collected from adult patients. 
The samples were cultured following routine micro-
biological diagnostic guidelines on Sabouraud agar 
and incubated at 30°C for 24–72 h until representative 
single colonies were formed. The ID 32 C yeast identi-
fication system (bioMérieux, France) was used for spe-
cies identification within the complexes.
Species identification within C. glabrata complex. 
The isolation of genomic DNA of the C. glabrata com-
plex isolates was performed using the Gene MATRIX 
Bacterial and Yeast Genomic DNA Purification Kit 
(EurX, Poland) following the manufacturer’s guidelines.
C. nivariensis and C. bracarensis identification 
within the C. glabrata complex. There were two stages 
of species identification within the Candida glabrata 
complex. In the first stage, the internal transcripted 
spacer 1 (ITS-1), characteristics of C. glabrata sensu 
stricto was identified using PCR. The NL-1 (5’-GCAT 
ATCAATAAGCGGAGGAAAAG’) and NL-4 (5’-GGT 
CCGTGTTTCAAGACGG’) primers were used for the 
amplification. The amplification were performed at fol-
lowing conditions: initial denaturation 94°C for 10 min, 
followed by 30 cycles of denaturation at 94°C for 
30 sec., annealing at 50°C for 1 min, elongation at 72°C, 
30 sec., and then final elongation at 72°C for 10 min. 
In the second stage the DNA was sequenced. Strains 
without the ITS-1 amplicon specific for C. glabrata 
had the D1/D2 region of the 26S rRNA sequenced. 
The NL-2A (5’-CTTGTTCGCTATCGGTCTC’) and 
NL-3A (5’-GAGACCGATAGCGAACAAG’) primers 
were used for sequencing (Kurtzman et al. 2003). The 
sequencing results were analyzed with the BLAST 
(the Basic Local Alignment Search Tool) software to 
compare the nucleotide sequences obtained with the 
reference sequence databases and calculate the statis-
tical significance.
The resistance of C. nivariensis to antifungals. 
E-test (bioMérieux, France) was used on RPMI agar; 
the minimal inhibitory concentrations (MIC [µg/ml]) 
for amphotericin B (AMB), fluconazole (FLU), itra-
conazole (ITC), posaconazole (POS), voriconazole 
(VOR), caspofungin (CAS), anidulafungin (ANF), 
and micafungin (MCF) were measured. MIC results 
(S – susceptible and R – resistant) of FLU, AMB, CAS, 
MCF, and ANF were interpreted following the Euro-
pean Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) guidelines (EUCAST 2018). In details, 
the interpretation for antifungals MICs was as follows: 
AMB ≤ 1 susceptible, > 1 resistant, FLU ≤ 0,002 sus-
ceptible, MCF ≤ 0,032 susceptible, > 0,032 resistant, 
ANF ≤ 0,064 susceptible, > 0,064 resistant, CAS – iso-
lates that are susceptible to anidulafungin as well as 
Candida nivariensis drug resistance and epidemiology3 305
micafungin should be considered susceptible to caspo-
fungin. MIC results (S – susceptible and R – resistant) 
of ITC, POS, and VOR the CLSI guidelines were used 
(CLSI 2008). In details, the interpretation for anti-
fungals MICs was as follows: ITC ≤ 0,125 susceptible, 
> 1  resistant, POS ≤ 1  susceptible, > 4  resistant, VOR 
≤ 1 susceptible, > 1 resistant.
Results
Species identification within the new C. glabrata 
complex. Four hundred forty-five strains were identi-
fied as C. glabrata and analyzed using PCR. For twenty-
four isolates (5.4% of all strains) the ITS-1 amplicon 
characteristic of C. glabrata sensu stricto was not 
observed and their D1/D2 regions of the 26S  rRNA 
were sequenced. They contained sequences 98% homo-
logous to C. nivariensis 26S rRNA. A representative 
BLAST analysis of the sequenced D1/D2 regions of the 
26S rRNA is shown in Fig. 1. Based on the sequenc-
ing results, no strains of C. bracarensis were identified. 
Table I presents the source of isolation of C. nivariensis 
and the drug susceptibility results.
Drug susceptibility of C. nivariensis. The strains 
of the new species were isolated from various clinical 
samples, including primarily sterile specimens. Their 
sensitivity to antifungals varied.
C. nivariensis strains were all susceptible to ampho-
tericin B, anidulafungin, micafungin, and caspo-
fungin. The MIC50 and MIC90 for amphotericin  B 
were 0.19 mg/l and 0.5 mg/l respectively, and the 
MIC50 and MIC90 for caspofungin were 0.19 mg/l 
and 0.19 mg/l respectively. The MIC50 = 0.012 mg/l, 
MIC90 = 0.016 mg/l, and micafungin MIC50 = 0.008 mg/l, 
MIC90 = 0.023 mg/l strains also had low anidulafungin.
Forty-one percent of C. nivariensis were resistant to 
itraconazole with the MIC in the range of 1.5–32 mg/l. 
The half of the strains (50%) was resistant to posa- 
conazole with the MIC of 1.5–32 mg/l. Eighty-three 
percent of C. nivariensis were susceptible to vori- 
conazole (the MIC in the range of 0.008–2.0 mg/l). All 
of the strains tested were intermediate-susceptible or 
resistant to fluconazole with the MIC in the range from 
0.25 to 256 mg/l.
Discussion
C. glabrata candidemias are on the increase, as it has 
been suggested in the literature due to the overuse of 
fluconazole treatments (Tapia et al. 2012; Colombo et al. 
2013; Quindós 2014). There is little information on the 
isolation of C. nivariensis and C. bracarensis. These are 
estimated to constitute 0.2–4.0% of the C. glabrata com-
plex (Bishop et al. 2008; Lockhart et al. 2009, Sharma 
et al. 2013). In the present study, C. nivariensis was more 
frequently isolated and made up for 5.4% (24 strains). 
Sharma et al. (2013)assessed 100 C. glabrata isolates 
and found five C. nivariensis strains. Chowdhary et al. 
(2010) analyzed 366 C. glabrata complex strains and 
established that two of them were C. nivariensis. Li et al. 
(2014) conducted a study on 301 isolates of C. glabrata 
complex cultured from vulvovaginal candidiasis cases. 
They found seven isolates of C. nivariensis. Similarly, 
the drug resistance of the new species within the 
C. glabrata complex is not well known. As there are very 
few species in the world identified as C. nivariensis or 
C. bracarensis, the information about their drug resist-
ance profile is very scarce. Li et al. (2014) showed that 
all C. nivariensis isolates were susceptible to nystatin 
and susceptible or susceptible dose-dependent to flu-
conazole, itraconazole, miconazole, and clotrimazole. 
The authors did not provide the MICs values of the 
antifungals tested.
Both species were susceptible to amphotericin  B; 
their MIC was not higher than 1.0 μg/ml. The interna-
tional data on C. nivariensis and C. bracarensis resist-
ance to azoles is different. The MIC values for azole 
(especially fluconazole) was high against some strains 
what may suggest that they could have the same resist-
ance mechanisms as C. glabrata sensu stricto. Previous 
studies suggested that the MIC values for echinocandin 
against C. nivariensis and C. bracarensis were low. None 
of these strains was proved resistant to this medication 
(Angoulvant et al. 2016).
C. glabrata sensu lato may nowadays be resistant to 
amphotericin B. In 1993 Pfaller et al. discovered 25% 
of C. glabrata sensu stricto with MIC > 1 μg/ml (Pfaller 
et al. 2004). More and more often the MIC value for 
amphotericin B against C. nivariensis was ≥ 0.5 μg/ml 
(Angoulvant et al. 2016). In the present study, both 
C. glabrata sensu stricto and C. nivariensis were suscep-
tible to amphotericin B.
The C. nivariensis strains evaluated in the present 
study were resistant to fluconazole (100%), itraconazole 
(41.7%), posaconazole (50%), and voriconazole (17%). 
One of the few studies of the British Reference Labora-
tory conducted by Borman et al. (2008) performed on 
16 clinical C. nivariensis isolates has reported similar 
results regarding C. nivariensis in vitro sensitivity to 
azoles. However, in contrary to their findings on the 
resistance to voriconazole and posaconazole (MIC50 at 
4 mg/l and 1 mg/l, respectively), in the present study 
only 17% of the strains were resistant to voriconazole 
and 50% to posaconazole (MIC50 at 0.125 mg/l and 
0.75 mg/l, respectively).
Other studies also suggested high value of the 
MIC for fluconazole (between 16–128 mg/l) against 
C. nivariensis (Fujita et al. 2007; Borman et al. 2008; 
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Sharma et al. 2013). In the present study, the MIC for 
fluconazole ranged from 0.25 to 256 mg/l.
In our opinion, all strains that had the MIC above 
0.002 mg/l should be considered as the intermediate 
susceptible to fluconazole since there are no estab-
lished interpretive breakpoint criteria to designate the 
C. nivariensis strain as either susceptible or resistant to 
fluconazole. Our opinion is supported by the EUCAST 
guidelines on the susceptibility to fluconazole of 
C. glabrata, which classify all stains above this value as 
the intermediate susceptible in­vitro.
In contrary to the findings of the present study, Li 
et al. (2014) proved that C. nivariensis was susceptible 
to fluconazole and itraconazole. Also Tay et al. (2014) 
established that C. nivariensis was susceptible to flu-
conazole and voriconazole.
Our study results also differ from the results pre-
sented by Huo et al. (2017) who studied 12 C. nivariensis 
strains and one C. bracarensis strain isolated from ten 
Chinese hospitals, and found that all strains were sus-
ceptible to azoles but not to fluconazole. Based on these 
findings we believe that susceptibility to azoles may vary 
geographically and can be attributed to the divergent 
use of azole in various locations. It is worth to mention 
that five of our isolates with the MIC value of 256 mg/l 
against fluconazole showed also the highest MICs val-
ues for itraconazole, posaconazole, and voriconazole. 
This finding may suggest cross-resistance among azoles, 
similar to the one described for C. glabrata (Panackal 
et al. 2006). This has to be elucidated for C. nivariensis.
Echinocandins, i.e. caspofungin, anidulafungin, and 
micafungin, are the newest available antifungal medi-
cation. However, the number of C. glabrata sensu lato 
strains with a lowered sensitivity to echinocandins have 
been described in several publications (Katiyar et al. 
2006; Cleary et al. 2008; Thompson et al. 2008; Garcia-
Effron et al. 2009; Arendrup et al. 2013).
Pfaller et al. (2011) evaluated 215 C. glabrata sensu 
lato isolates and established that 16.7% of them were 
resistant to echinocandins. Low values of the MIC for 
echinocandin against C. nivariensis have already been 
reported. In the present study, all strains C. nivariensis 
were susceptible to echinocandins.
Our data are in concordance with the data pub-
lished by Morales-Lόpez et al. (2017) regarding the 
strains isolated during 30  years in Argentina. They 
tested resistance to echinocandins of five C. nivarien­
sis strains isolated from a collection of 122 C. glabrata 
complex strains. All C. nivariensis strains tested were 
resistant to echinocandins with the MICs ranging 
from 0.015 to 0.03 mg/l and from 0.06 to 0.13 mg/l 
for anidulafungin and caspofungin, respectively. Since 
the relatively low number of C. nivariensis has already 
been examined worldwide it is difficult to estimate the 
real resistance rate to echinocandins. C. glabrata sensu 
stricto simultaneous resistance to azoles and echino-
candins was observed in the past years and it is an 
alarming phenomenon (Pfaller et al. 2011; Alexander 
et al. 2013; Morales-López et al. 2017). Cleveland et al. 
(2015) observed a simultaneously increased resist-
ance to azoles and echinocandins, from 1.8% to 2.6% 
within five years of observation. In the present study, 
any C. nivariensis strain was simultaneously resistant to 
azoles and echinocandins.
Since data on the epidemiology and susceptibility 
to antifungals of C. nivariensis are limited, our study 
may enrich the global knowledge about its epidemi-
ology and drug resistance. Moreover, it indicates the 
need for proper microbiological analysis with the use 
of molecular methods or with the updated spectra 
of the matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS). 
C. nivariensis should be recognized as an emerging, 
azoles-resistant pathogen.
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